Twist bioscience12/31/2023 ![]() ![]() For a description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist Bioscience’s business in general, see Twist Bioscience’s risk factors set forth in Twist Bioscience’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on Augand subsequent filings with the SEC. Forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Bioscience’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. This press release contains forward-looking statements. Legal Notice Regarding Forward-Looking Statements The webcast replay will be available for two weeks.įollow us on Twitter | Facebook | LinkedIn | YouTube To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. Upon registration, all telephone participants will receive the dial-in number along with a unique PIN number that can be used to access the call. The conference call will be webcast live through the Investor Relations section under the "Company" tab at Those parties interested in participating via telephone must register on the Company’s Investor Relations website or by clicking here. Eastern Time to discuss its financial results and provide an update on the company’s business. The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Twist will issue its financial results for the fiscal 2022 fourth quarter and full year ended September 30, 2022, before the opening of the market on Friday, November 18, 2022. Twist remains focused on its mission to improve health and sustainability by manufacturing DNA at scale and on growing its business, including shipping product from the Factory of the Future in January 2023. In addition, Twist’s inaugural ESG report details the company’s environmental, social and governance practices at length, which Twist fully stands behind. ![]() Unlike the author of the short-seller report, Twist is a public company, and is committed to communicating truthfully, creating value for all shareholders, and being good stewards of capital. Twist believes that the short-seller report issued by Scorpion Capital is highly misleading, with many distortions and inaccuracies. SOUTH SAN FRANCISCO, Calif., November 15, 2022-( BUSINESS WIRE)- Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today addressed a misleading short-seller report issued by Scorpion Capital. Twist to report fiscal Q4 and full year 2022 financial results before market Friday, November 18, and host a conference call at 8:00 a.m. ![]()
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |